HIV pathogenesis: Dynamics and genetics of viral populations and infected cells

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 1, 2013, Pages

  Coffin, John ^a   Swanstrom, Ronald ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872040237     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012526     Document Type: Article

References (53)

1. Arts E.J., Hazuda DJ. 2011. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a007161.
2. + T cells. J Virol 80: 6441-6457.
3. Buzon M.J., Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, et al. 2011. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 16: 460-465.
4. Chersich M.F., Gray GE. 2005. Progress and emerging challenges in preventing mother-to-child transmission. Curr Infect Dis Rep 7: 393-400.
5. Chun T.W., Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
6. Coffin JM. 1995. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267: 483-488.
7. Craigie R., Bushman FD. 2011. HIV DNA integration. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a006890.
8. + T cell control of HIV-A known unknown. PLoS Pathog 6: e1000728. doi: 10.1371/journal.ppat.1000728.
9. Dinoso J.B., Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L., O'Shea A, Callender M, Spivak A, Brennan T, et al. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci 106: 9403-9408.
10. Fauci A.S., Desrosiers RC. 1997. Pathogenesis of HIVand SIV. In Retroviruses (ed. Coffin JM, et al.), pp. 587-635. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
11. Gandhi R.T., Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C., Bastow B, Para M, Lai J, Siliciano RF, et al. 2010. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtidecontaining antiretroviral therapy. J Infect Dis 201: 293-296.
12. Ho D.D., Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV infection. Nature 373: 123-126.
13. HuWS, Hughes SH. 2011. HIV-1 reverse transcription. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a006882.
14. + T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189: 991-998.
15. Joos B., Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, Hirschel B, Weber R, Trkola A, Gunthard HF. 2008. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci 105: 16725-16730.
16. + T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci 108: 11199-11204.
17. Jung A., Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, Meese E, Wain-Hobson S, Meyerhans A. 2002. Recombination: Multiply infected spleen cells in HIV patients. Nature 418: 144.
18. Karn J., Stoltzfus CM. 2011. Transcriptional and post-transcriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a006916.
19. Kearney M., Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors J.W., Rao V, Coffin JM, Palmer S. 2009. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 83: 2715-2727.
20. Keele B.F., Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci 105: 7552-7557.
21. Kitrinos K.M., Nelson JA, Resch W, Swanstrom R. 2005. Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol 79: 10627-10637.
22. + lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 6: e1000747.
23. Korber B., Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. 2001. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58: 19-42.
24. Kuiken C., Korber B, Shafer RW. 2003. HIV sequence databases. AIDS Rev 5: 52-61.
25. Lackner A.A., Lederman MM, Rodriguez B. 2011. HIV pathogenesis-The host. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a007005.
26. Maldarelli F. 2011. Targeting viral reservoirs: Ability of antiretroviral therapy to stop viral replication. Curr Opin HIV AIDS 6: 49-56.
27. Maldarelli F., Palmer S, King MS, Wiegand A, Polis MA, Mican J., Kovacs JA, Davey RT, Rock-Kress D, Dewar R, et al. 2007. ARTsuppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3: e46. doi: 10.1371/journal.ppat.0030046.
28. Malim M.H., Bieniasz PD. 2011. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a006940.
29. Mansky L.M., Temin HM. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
30. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S., McNulty S, Metcalf JA, Acosta E, Rehm C, et al. 2010. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50: 912-919.
31. Mellors J.W., Rinaldo CRJ, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170.
32. Mens H., Kearney M, Wiegand A, Shao W, Schonning K, Gerstoft J., Obel N, Maldarelli F, Mellors JW, Benfield T, et al. 2010. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 84: 12971-12981.
33. Murray J.M., Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA. 2007. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21: 2315-2321.
34. Palmer S., Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M., Dewar RL, Planta A, Liu S, Metcalf JA, et al. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41: 4531-4536.
35. Palmer S., Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H., Rock D, Falloon J, Davey RT Jr, Dewar RL, et al. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406-413.
36. Palmer S., Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun S.C., Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci 105: 3879-3884.
37. Perelson A.S., Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, HoDD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
38. Richman D.D., Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci 100: 4144-4149.
39. Rouzine I.M., Coffin JM. 2005. Evolution of human immunodeficiency virus under selection and weak recombination. Genetics 170: 7-18.
40. Ruff C.T., Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R., Gange S, Quinn TC, Siliciano RF, et al. 2002. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 76: 9481-9492.
41. + lymphocytes. Science 283: 857-860.
42. Shankarappa R., Margolick JB, Gange SJ, Rodrigo AG, Upchurch D., Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, et al. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 7312: 10489-10502.
43. Sharkey M.E., Stevenson M. 2001. Two long terminal repeat circles and persistent HIV-1 replication. Curr Opin Infect Dis 14: 5-11.
44. Shaw G.M., Hunter E. 2011. HIV transmission. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a006965.
45. Sigal A., Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477: 95-98.
46. Siliciano R.F., Greene WC. 2011. HIV latency. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a007096.
47. Svarovskaia E.S., Cheslock SR, Zhang WH, Hu WS, Pathak VK. 2003. Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci 8: D117-D134.
48. SwanstromR, Coffin J. 2011. HIV-1 pathogenesis: The virus. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a007443.
49. Tobin N.H., Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, Pawluk DM, Mohan KM, Lewis PF, Mullins JI, et al. 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol 79: 9625-9634.
50. Walker B., McMichael A. 2011. The T-cell response to HIV. Cold Spring Harb Perspect Med doi: 10.1101/cshper spect.a007054.
51. Wei X., Ghosh S, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
52. + T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog 61: e1000748.
53. Zhang L., Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S., Talal A, Racz P, Perelson AS, Korber BT, et al. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340: 1605-1613.